ClinicalTrials.gg
CompletedNCT03088540Updated Nov 12, 2026Results posted

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Pemetrexed and Paclitaxel in Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell and Non-small-cell Lung Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 192 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 29
712 · median 61
Started
2017
the only one that year
Phase 3
5 of 29
2 open now
Registered
1st of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 5 in phase 3, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objectives of the study are:

  • To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells
  • To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells

The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies

Read the detailed description

There is option to join genomics sub-study.

03

Conditions studied

  • Carcinoma,Non-Small-Cell Lung
  • Lung Carcinomas, Non-Small-Cell
  • Non-small-cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer

Keywords

  • Previous Smoker
  • Current Smoker
  • Stage IIIB
  • Stage IIIC
  • Stage IV
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

A patient must meet the following criteria to be eligible for inclusion in the study:

  1. Patients with or cytologically documented squamous or non squamous NSCLC with stage IIIB or stage IIIC disease who are not candidates for treatment with definitive concurrent chemoradiation or patients with stage IV disease who received no prior systemic treatment for recurrent or NSCLC
  2. Archival or newly obtained formalin-fixed tumor tissue from a metastatic/recurrent site, which has not previously been irradiated
  3. Tumor cells expressing PD L1 above a specific percentage of tumor cells by IHC performed by the central laboratory
  4. At least 1 radiographically measureable lesion per 1.1
  5. performance status of ≤1
  6. Anticipated of at least 3 months
  7. Adequate organ and bone marrow function

Key Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

  1. Patients that have never smoked, defined as smoking \<100 cigarettes in a lifetime
  2. Active or untreated or spinal cord compression
  3. Patients with tumors tested positive for EGFR gene mutations, ALK gene translocations, or ROS1 fusions
  4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to randomization
  6. Patients with active, known, or suspected disease that has required systemic therapy in the past 2 years
  7. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization
  8. Another that is progressing or requires treatment
  9. Uncontrolled infection with or or (HIV) or diagnosis of immunodeficiency
  10. Active infection requiring systemic therapy within 14 days prior to randomization
  11. Prior therapy with anti-PD 1 or anti-PD L1
  12. Treatment-related immune-mediated AEs from immune-modulatory agents
  13. Receipt of an drug or device within 30 days
  14. Receipt of a within 30 days of planned start of study medication
  15. Major surgery or significant traumatic injury within 4 weeks prior to first dose
  16. Documented allergic or acute reaction attributed to antibody treatments
  17. Known psychiatric or substance abuse disorder that would interfere with participation with the requirements of the study, including current use of any illicit drugs
  18. Pregnant or breastfeeding women
  19. Women of or men who are unwilling to practice highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
712 participants (actual)

Study arms

  • Active comparator
    Standard-of-care chemotherapy

    Standard-of-care chemotherapy will administered from these options: Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance

    Drug: Pemetrexed · Drug: Paclitaxel · Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin

  • Experimental
    cemiplimab

    cemiplimab regimen as monotherapy as per study protocol

    Drug: cemiplimab

Interventions

  • Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin

  • Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin

  • Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin

  • Administered with either Pemetrexed, Paclitaxel or gemcitabine.

  • Administered with either Pemetrexed, Paclitaxel or gemcitabine.

  • Patients will be administered cemiplimab as per protocol.

    Also known as: REGN2810, Libtayo

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to 94 months

  2. Progression-free Survival (PFS) Per Blinded IRC

    PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

    Time frame: Up to 94 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per IRC

    ORR was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by IRC per RECIST 1.1.

    Time frame: Up to 73.5 months

  2. Best Overall Response (BOR) Per IRC

    BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

    Time frame: Up to 73.5 months

  3. Duration of Response (DoR) Per IRC

    DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.

    Time frame: Up to 73.5 months

  4. Change From Baseline in Global Health Status/Quality of Life (QoL) Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (physical, role, cognitive, emotional, social), 9 symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items: "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" Each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a score ranging from 0 to 100; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

    Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39

  5. Change From Baseline in Coughing Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)

    EORTC QLQ-LC13 is a 13-item questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia). Reported here are the EORTC lung cancer coughing scores only. Scores were calculated and transformed to a range from 0 to 100, with a higher score representing a higher level of symptoms/problems and a negative change from baseline value indicating reduction (i.e. improvement) in symptoms.

    Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 94 months

  7. Number of Participants With Serious TEAEs

    Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

    Time frame: Up to 94 months

  8. Number of Deaths During the On-Treatment Period

    The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

    Time frame: Up to approximately 28 months

  9. Number of Participants With Laboratory Abnormalities

    Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.

    Time frame: Up to approximately 28 months

  10. Trough Concentration (Ctrough) of Cemiplimab in Serum

    Time frame: Up to 73.5 months

  11. Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum

    Time frame: Up to 73.5 months

  12. Number of Participants With Anti-Cemiplimab Antibodies (ADA)

    The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response

    Time frame: Up to 73.5 months

  13. Number of Participants With Neutralizing Antibodies (NAb)

    The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive

    Time frame: Up to 73.5 months

07

Results

Posted Jun 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneCemiplimabChemotherapy
Started357355
Randomized and treated356343
Completed treatment73161
Completed7535
Not completed282320
Withdrew: Adverse event10
Withdrew: Death157184
Withdrew: Lost to follow-up106
Withdrew: Subject decision3324
Withdrew: Sponsor decision11
Withdrew: Physician decision36
Withdrew: Disease progression3535
Withdrew: Withdrawal by subject3956
Withdrew: Other than specified38

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to 94 months
Reported as:
Median · months
Overall Survival (OS)
monthsCemiplimabChemotherapy
Overall Survival (OS)23.4 (19.4 to 27.6)13.7 (11.2 to 16.2)
Statistical analysis
  • Cemiplimab vs Chemotherapy · Stratified log-rank · p = <0.0001 (All analyses based on final database lock (DBL) were descriptive only with p-values reported as nominal.) · Hazard ratio (hr): 0.661 · 95% CI 0.553 to 0.790
PrimaryProgression-free Survival (PFS) Per Blinded IRC

PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

Time frame:
Up to 94 months
Reported as:
Median · months
Progression-free Survival (PFS) Per Blinded IRC
monthsCemiplimabChemotherapy
Progression-free Survival (PFS) Per Blinded IRC6.3 (4.6 to 8.3)5.3 (4.3 to 6.0)
Statistical analysis
  • Cemiplimab vs Chemotherapy · Stratified log-rank · p = <0.0001 (All analyses based on final DBL were descriptive only with p-values reported as nominal.) · Hazard ratio (hr): 0.559 · 95% CI 0.469 to 0.665
SecondaryObjective Response Rate (ORR) Per IRC

ORR was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by IRC per RECIST 1.1.

Time frame:
Up to 73.5 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per IRC
percentage of participantsCemiplimabChemotherapy
Objective Response Rate (ORR) Per IRC42.3 (37.1 to 47.6)21.4 (17.3 to 26.0)
Statistical analysis
  • Cemiplimab vs Chemotherapy · Stratified Cochran-Mantel-Haenszel · p = <0.0001 (All analyses based on final DBL were descriptive only with p-values reported as nominal.) · Odds ratio (or): 2.691 · 95% CI 1.936 to 3.740
SecondaryBest Overall Response (BOR) Per IRC

BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

Time frame:
Up to 73.5 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR) Per IRC
ParticipantsCemiplimabChemotherapy
Complete Response (CR)304
Partial Response (PR)12172
Stable Disease (SD)90175
Non-CR/Non-PD24
Progressive Disease (PD)7656
Not Evaluable (NE)3844
SecondaryDuration of Response (DoR) Per IRC

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.

Time frame:
Up to 73.5 months
Reported as:
Median · months
Duration of Response (DoR) Per IRC
monthsCemiplimabChemotherapy
Duration of Response (DoR) Per IRC24.1 (18.6 to 35.2)5.9 (4.3 to 6.3)
SecondaryChange From Baseline in Global Health Status/Quality of Life (QoL) Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (physical, role, cognitive, emotional, social), 9 symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items: "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" Each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a score ranging from 0 to 100; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

Time frame:
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39
Reported as:
Mean · score on a scale
Change From Baseline in Global Health Status/Quality of Life (QoL) Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
score on a scaleCemiplimabChemotherapy
Cycle 2, Day 1 (C2D1)4.92 ± 20.4550.45 ± 19.291
C3D17.23 ± 21.9281.25 ± 21.019
C4D18.13 ± 21.9252.43 ± 21.795
C5D18.27 ± 24.4221.88 ± 21.803
C6D19.64 ± 22.9103.00 ± 20.909
C9D110.19 ± 23.3592.55 ± 20.142
C12D111.11 ± 23.077-4.17 ± 19.543
C15D110.88 ± 24.7055.36 ± 19228
C18D110.10 ± 26.792-3.03 ± 22.753
C21D113.42 ± 25.060-1.19 ± 11.210
C24D110.76 ± 22.6761.19 ± 12.199
C27D112.50 ± 24.225-3.33 ± 12.638
C30D111.74 ± 24.358-4.17 ± 10.758
C33D19.62 ± 26.3550.00 ± 11.785
C36D111.69 ± 24.9284.17 ± 5.893
C39D1—8.33
SecondaryChange From Baseline in Coughing Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)

EORTC QLQ-LC13 is a 13-item questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia). Reported here are the EORTC lung cancer coughing scores only. Scores were calculated and transformed to a range from 0 to 100, with a higher score representing a higher level of symptoms/problems and a negative change from baseline value indicating reduction (i.e. improvement) in symptoms.

Time frame:
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39
Reported as:
Mean · score on a scale
Change From Baseline in Coughing Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)
score on a scaleCemiplimabChemotherapy
Cycle 2, Day 1 (C2D1)-4.12 ± 25.777-4.32 ± 26.406
C3D1-8.60 ± 29.824-8.56 ± 29.059
C4D1-11.19 ± 28.598-11.41 ± 30.181
C5D1-12.41 ± 31.065-9.86 ± 31.752
C6D1-13.33 ± 30.251-11.11 ± 28.142
C9D1-13.12 ± 29.601-12.24 ± 31.691
C12D1-13.22 ± 28.179-5.56 ± 30.429
C15D1-15.65 ± 27.116-19.05 ± 31.254
C18D1-16.16 ± 27.777-15.15 ± 27.340
C21D1-17.70 ± 28.546-19.05 ± 26.227
C24D1-18.30 ± 28.773-28.57 ± 23.002
C27D1-17.75 ± 34.041-26.67 ± 27.889
C30D1-18.94 ± 31.882-16.67 ± 33.333
C33D1-18.38 ± 30.222-8.33 ± 41.944
C36D1-22.22 ± 28.527-16.67 ± 23.570
C39D1—0.00
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 94 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCemiplimabChemotherapy
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)330329
SecondaryNumber of Participants With Serious TEAEs

Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

Time frame:
Up to 94 months
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs
ParticipantsCemiplimabChemotherapy
Number of Participants With Serious TEAEs127101
SecondaryNumber of Deaths During the On-Treatment Period

The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

Time frame:
Up to approximately 28 months
Reported as:
Count of participants · Participants
Number of Deaths During the On-Treatment Period
ParticipantsCemiplimabChemotherapy
Number of Deaths During the On-Treatment Period8780
SecondaryNumber of Participants With Laboratory Abnormalities

Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.

Time frame:
Up to approximately 28 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsCemiplimabChemotherapy
Hematology230301
Electrolytes278253
Liver Function255195
Chemistry296258
Coagulation4021
SecondaryTrough Concentration (Ctrough) of Cemiplimab in Serum
Time frame:
Up to 73.5 months
Reported as:
Mean · milligrams per liter (mg/L)
Trough Concentration (Ctrough) of Cemiplimab in Serum
milligrams per liter (mg/L)Cemiplimab
Trough Concentration (Ctrough) of Cemiplimab in Serum59.7 ± 28.4
SecondaryMaximum Plasma Concentration (Cmax) of Cemiplimab in Serum
Time frame:
Up to 73.5 months
Reported as:
Mean · mg/L
Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum
mg/LCemiplimab
Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum184 ± 101
SecondaryNumber of Participants With Anti-Cemiplimab Antibodies (ADA)

The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response

Time frame:
Up to 73.5 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-Cemiplimab Antibodies (ADA)
ParticipantsCemiplimab
Negative241
Pre-existing9
Treatment-emergent Response5
SecondaryNumber of Participants With Neutralizing Antibodies (NAb)

The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive

Time frame:
Up to 73.5 months
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies (NAb)
ParticipantsCemiplimab
NAb Negative255
NAb Positive0

Adverse events

Collected over From signing of first informed consent up to 94 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cemiplimab178/356 (50%)131/356 (36.8%)287/356 (80.6%)
Extended Treatment: Cemiplimab + Chemotherapy60/85 (70.6%)23/85 (27.1%)70/85 (82.4%)
Chemotherapy116/343 (33.8%)103/343 (30%)319/343 (93%)
Crossover: Chemotherapy to Cemiplimab141/191 (73.8%)57/191 (29.8%)141/191 (73.8%)
Most frequent serious events
Showing 10 of 210
Most frequent serious events
EventCemiplimabExtended Treatment: Cemiplimab + ChemotherapyChemotherapyCrossover: Chemotherapy to Cemiplimab
PneumoniaInfections and infestations22/3560/8520/3439/191
AnaemiaBlood and lymphatic system disorders6/3563/8516/3436/191
PneumonitisRespiratory, thoracic and mediastinal disorders8/3561/850/3436/191
DeathGeneral disorders6/3562/852/3434/191
DiarrhoeaGastrointestinal disorders1/3562/851/3430/191
Febrile neutropeniaBlood and lymphatic system disorders2/3560/858/3430/191
Urinary tract infectionInfections and infestations1/3561/853/3434/191
ThrombocytopeniaBlood and lymphatic system disorders0/3560/857/3430/191
DyspnoeaRespiratory, thoracic and mediastinal disorders7/3561/856/3432/191
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/3561/852/3430/191
Most frequent other events
Showing 10 of 44
Most frequent other events
EventCemiplimabExtended Treatment: Cemiplimab + ChemotherapyChemotherapyCrossover: Chemotherapy to Cemiplimab
AnaemiaBlood and lymphatic system disorders70/35627/85175/34339/191
NauseaGastrointestinal disorders29/35616/8599/34310/191
AlopeciaSkin and subcutaneous tissue disorders4/35619/8586/3433/191
Decreased appetiteMetabolism and nutrition disorders49/3567/8566/34319/191
FatigueGeneral disorders48/3567/8565/34319/191
DiarrhoeaGastrointestinal disorders33/35616/8532/3439/191
NeutropeniaBlood and lymphatic system disorders10/35612/8562/3435/191
ConstipationGastrointestinal disorders29/3566/8558/34311/191
ThrombocytopeniaBlood and lymphatic system disorders7/3563/8552/3436/191
VomitingGastrointestinal disorders18/3567/8549/3436/191

Baseline characteristics

The full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)CemiplimabChemotherapyTotal
Mean63.0 ± 8.1863.3 ± 8.5563.1 ± 8.36
Sex: Female, Male
Sex: Female, Male(Participants)CemiplimabChemotherapyTotal
Female4461105
Male313294607
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CemiplimabChemotherapyTotal
Hispanic or Latino362662
Not Hispanic or Latino321328649
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CemiplimabChemotherapyTotal
White309306615
Black or African American134
Asian393877
American Indian or Alaska Native6814
Other202
08

Study locations

192 sites
  • Clinical Study Site
    Albury, New South Wales, Australia
  • Clinical Study Site
    Wollongong, New South Wales, Australia
  • Clinical Study Site
    Fitzroy, Australia
  • Clinical Study Site
    Minsk, Belarus
  • Clinical Study Site
    Mogilev, Belarus
  • Clinical Study Site 1
    Porto Alegre, Rio Grande do Sul, Brazil
  • Clinical Study Site
    Barretos, Brazil
  • Clinical Study Site
    Curitiba, Brazil
  • Clinical Study Site
    Joinville, Brazil
  • Clinical Study Site
    Lajeado, Brazil
  • Clinical Study Site
    Mogi das Cruzes, Brazil
  • Clinical Study Site
    Passo Fundo, Brazil
  • Clinical Study Site
    Pelotas, Brazil
  • Clinical Study Site 2
    Porto Alegre, Brazil
  • Clinical Study Site 3
    Porto Alegre, Brazil
  • Clinical Study Site
    Recife, Brazil
  • Clinical Study Site
    Rio de Janeiro, Brazil
  • Clinical Study Site
    Salvador, Brazil
  • Clinical Study Site
    Santa Cecília, Brazil
  • Clinical Study Site
    São José do Rio Preto, Brazil
  • Clinical Study Site #3
    São Paulo, Brazil
  • Clinical Study Site #4
    São Paulo, Brazil
  • Clinical Study Site 1
    São Paulo, Brazil
  • Clinical Study Site 2
    São Paulo, Brazil
  • Clinical Study Site
    Dobrich, Bulgaria
  • Clinical Study Site
    Gabrovo, Bulgaria
  • Clinical Study Site
    Recoleta, Chile
  • Clinical Study Site
    Santiago, Chile
  • Clinical Study Site
    Temuco, Chile
  • Clincial Study Site
    Viña del Mar, Chile
  • Clinical Study Site
    Lanshan, Shandong, China
  • Clinical Study Site
    Guangdong, China
  • Clinical Study Site
    Harbin, China
  • Clinical Study Site
    Linyi, China
  • Clinical Study Site 1
    Shanghai, China
  • Clinical Study Site 2
    Shanghai, China
  • Clinical Study Site 1
    Tianjin, China
  • Clinical Study Site 2
    Tianjin, China
  • Clinical Study Site
    Xuzhou, China
  • Clinical Study Site
    Zhejiang, China
  • Clinical Study Site
    Barranquilla, Colombia
  • Clinical Study Site
    Bogotá, Colombia
  • Clinical Study Site
    Floridablanca, Colombia
  • Clinical Study Site
    Nový Jičín, Czechia
  • Clinical Study Site
    Pelhřimov, Czechia
  • Clinical Study Site
    Prague, Czechia
  • Clinical Study Site
    Batumi, Georgia
  • Clinical Study Site #6
    Tbilisi, Georgia
  • Clinical Study Site 1
    Tbilisi, Georgia
  • Clinical Study Site 2
    Tbilisi, Georgia
  • Clinical Study Site 3
    Tbilisi, Georgia
  • Clinical Study Site 4
    Tbilisi, Georgia
  • Clinical Study Site 5
    Tbilisi, Georgia
  • Clinical Study Site
    Pátrai, Achaia, Greece
  • Clinical Study Site
    Cholargós, Attica, Greece
  • Clinical Study Site 1
    Athens, Greece
  • Clinical Study Site 2
    Athens, Greece
  • Clinical Study Site 3
    Athens, Greece
  • Clinical Study Site
    Larissa, Greece
  • Clinical Study Site
    Pylaia, Greece
  • Clinical Study Site 1
    Thessaloniki, Greece
  • Clinical Study Site 2
    Thessaloniki, Greece
  • Clinical Study Site 3
    Thessaloniki, Greece
  • Clinical Study Site
    Gyula, Bekes County, Hungary
  • Clinical Study Site
    Tatabánya, Komárom-Esztergom, Hungary
  • Clinical Study Site
    Farkasgyepű, Veszprém megye, Hungary
  • Clinical Study Site
    Budapest, Hungary
  • Clinical Study Site
    Debrecen, Hungary
  • Clinical Study Site
    Zalaegerszeg, Hungary
  • Clinical Study Site
    Amman, Jordan
  • Clinical Study Site
    Irbid, Jordan
  • Clinical Study Site
    Bsalîm, Lebanon
  • Clinical Study Site
    Mazraat ech Choûf, Lebanon
  • Clinical Study Site
    Sidon, Lebanon
  • Clinical Study Site
    Kampung Baharu Nilai, Malaysia
  • Clinical Study Site #1
    Kuala Lumpur, Malaysia
  • Clinical Study Site #2
    Kuala Lumpur, Malaysia
  • Clinical Study Site
    Kuching, Malaysia
  • Clinical Study Site
    Pulau Pinang, Malaysia
  • Clinical Study Site
    Tanjong Bungah, Malaysia
  • Clinical Study Site
    Coahuila, Mexico
  • Clinical Study Site
    Cuautitlán, Mexico
  • Clinical Study Site
    Jalisco, Mexico
  • Clinical Study Site
    León, Mexico
  • Clinical Study Site 1
    Monterrey, Mexico
  • Clinical Study Site 2
    Monterrey, Mexico
  • Clinical Study Site 3
    Monterrey, Mexico
  • Clinical Study Site
    Oaxaca City, Mexico
  • Clinical Study Site
    San Luis Potosí City, Mexico
  • Clinical Study Site
    Bacolod City, Philippines
  • Clinical Study Site
    Batangas, Philippines
  • Clinical Study Site
    Cebu, Philippines
  • Clinical Study Site
    City of Taguig, Philippines
  • Clinical Study Site
    Davao City, Philippines
  • Clinical Study Site 1
    Manila, Philippines
  • Clinical Study Site 2
    Manila, Philippines
  • Clinical Study Site #1
    Quezon City, Philippines
  • Clinical Study Site #2
    Quezon City, Philippines
  • Clinical Study Site
    Dąbrowa Górnicza, Poland
  • Clinical Study Site
    Gdynia, Poland

Showing the first 100 of 192 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gandara DR, Gumus M, Kilickap S, Sezer A, Bondarenko I, Ozguroglu M, Gogishvili M, Yan E, Jia X, Kim E, Seebach F, Quek RGW. Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. Cancer. 2026 Mar 15;132(6):e70339. doi: 10.1002/cncr.70339. PubMed 41808570 ↗
  • Perez J, Kerr KM, Baker B, Fang F, Li J, McDonald J, Li S, Gao B, Pouliot JF, Seebach F, Lowy I, Gullo G, Herman G, Hamilton J, Rietschel P, McGuire K. Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab. JCO Precis Oncol. 2025 Sep;9:e2500177. doi: 10.1200/PO-25-00177. Epub 2025 Sep 24. PubMed 40991883 ↗
  • Kilickap S, Baramidze A, Sezer A, Ozguroglu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025 Jul;20(7):941-954. doi: 10.1016/j.jtho.2025.03.033. Epub 2025 Mar 19. PubMed 40118215 ↗
  • Ozguroglu M, Kilickap S, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. PubMed 37591293 ↗
  • Gumus M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Ozguroglu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477. Epub 2022 Oct 29. PubMed 36308296 ↗
  • Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. PubMed 33581821 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Apr 2025, 94 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 94 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2017
First posted
Mar 23, 2017
StartActual
May 29, 2017
Primary completionActual
Apr 18, 2025
CompletionActual
Apr 18, 2025
Results first posted
Jun 25, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, site details and references
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03088540
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 23, 2017
Start date
May 29, 2017
Primary completion
Apr 18, 2025
Completion
Apr 18, 2025
Results posted
Jun 25, 2026
Last update
Nov 12, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion